Unicycive Therapeutics Inc
UNCY
$1.15
Closing
▲7.48%
1D
▲32.53%
YTD
Market cap
$39.97M
52 week high
$1.82
52 week low
$0.49
Volume
52,625
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$39.97M
Analysts' Rating
BUY
Price Target (Mean)
3.83333
Total Analysts
3
P/E
Operating Margin
0.00%
Beta
Revenue Growth (Annual)
0.00%
52 week high
$1.82
52 week low
$0.49
Div. Yield
%
EPS Annual Growth
-55.17
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis (CKD), and UNI 494, for treatment of acute kidney injury (AKI). Renazorb is initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum). UNI 494 is initially developed by and licensed to it from Sphaera Pharmaceuticals, respectively.
